HAYA Therapeutics · 17 hours ago
Senior Scientist II, Data Science (CompBio for Translation and Biomarkers in Cardio-Renal-Metabolics)
HAYA Therapeutics is a biotech company focused on RNA-guided genome-targeting therapies for chronic diseases. They are seeking a Senior Scientist II in Data Science to lead the transformation of complex datasets into decision-ready scientific outputs, ensuring rigor and credibility in the cardiac and cardiorenal space.
BiotechnologyGeneticsHealth CareMedicalTherapeutics
Responsibilities
Act as a lead scientific communicator, showcasing HAYA’s data science platform and analytical capabilities to external partners, investors, and at scientific conferences
Drive the creation of high-quality, high-impact data packages and visualizations from analyses across multiple programs to support decision-making and external business development
Serve as the quality control gatekeeper for all outgoing material in the cardio-renal-metabolic context; review and validate computational outputs to ensure biological accuracy and rigorous standards before dissemination
Lead the computational strategy for prioritizing pharmacodynamic (PD), predictive, and prognostic biomarkers from multi-omics datasets to support clinical development in the Cardio-Renal-Metabolic space
Define and execute the data strategy to translate preclinical findings (in vitro/in vivo) into clinically relevant hypotheses, ensuring alignment with industrial drug development standards
Apply advanced statistical and machine learning approaches to stratify patient populations and define responder signatures for HAYA’s therapeutics in heart failure and related metabolic conditions
Perform and oversee end-to-end analysis of bulk, single-cell, and single-nuclei transcriptomics and epigenomics data, acting as a subject matter expert specifically within cardiac, renal, and metabolic areas
Integrate multi-omics data from in-house and public sources to uncover novel biology, disease-specific cell states, and perturbation signatures relevant to cardiac diseases (e.g., HCM, HF)
Establish analysis strategies to handle translational datasets, setting the standard for the entire team
Synthesize data from multiple independent datasets to construct clear, biologically meaningful narratives for technical and non-technical audiences
Be able to drive high-quality material generation autonomously, taking over major responsibilities from other team members
Qualification
Required
PhD in computational sciences (e.g., bioinformatics, computer science) or life sciences with a strong computational focus
6+ years of relevant industry post-doctoral experience
Expertise with the biological interpretation of multi-omics transcriptomic data (single-cell/nuclei RNA-Seq and bulk RNA-Seq in particular)
Proficiency in R or Python and data science frameworks: HPC/cloud-based environments, Jupyter notebooks, Ai-augmented data science (e.g., Cursor, Windsurf)
Demonstrated industrial experience in computational biomarker discovery pipelines, including feature selection, validation, and clinical utility assessment
Comprehensive experience with translational and industrial/biotech settings in the Cardio-Renal-Metabolic therapeutic area
Proven ability to bridge the gap between early discovery and clinical translation, utilizing computational biology to support target and biomarker validation and translation
Exceptional ability to present complex data to diverse audiences (business, clinical, scientific) and experience acting as a reviewer/approver for scientific content
Exceptional ability to generate high-quality data packages and results for internal and external audiences in an autonomous way
Preferred
Experience with epigenomic data (e.g., ATAC-Seq, CUT&RUN) is highly desirable
Experience with ASO / siRNA-related data interpretation is highly desirable
Company
HAYA Therapeutics
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.
Funding
Current Stage
Early StageTotal Funding
$1.11BKey Investors
InnosuisseEli LillyVenture Kick
2025-09-01Grant
2025-05-08Series A· $65M
2024-09-04Undisclosed· $1B
Recent News
2025-12-29
Business Wire
2025-11-24
2025-11-08
Company data provided by crunchbase